Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.

Juergen K RockstrohVicente SorianoFrank PlonskiMeena BansalGerd FätkenheuerCatherine B SmallDavid M AsmuthGilles PialouxGeoffrey MukwayaShyla JagannathaJayvant HeeraJuan A Pineda

Published in: HIV clinical trials (2018)

The use of maraviroc does not increase hepatotoxicity in HIV-1-infected subjects co-infected with HCV and/or HBV through 48 weeks of treatment.

Keyphrases

hiv infected
antiretroviral therapy
human immunodeficiency virus
double blind
hiv positive
hepatitis c virus
hiv aids
hiv infected patients
placebo controlled
clinical trial
hepatitis b virus
phase iii
randomized controlled trial
south africa
combination therapy
liver failure